Login or Register
Biomedical Learning Institute Taught by the Experts
Thought Leaders		 Biomedical Learning Institute
Please Note: The Oncology Learning Center has changed its name to Biomedical Learning Institute
Overview | Agenda | Hotel Accommodations | Registration
Symposium Co-Chairs

Paul A Bunn Jr MD
Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Aurora, CO
Executive Director, USA
International Association for the Study of Lung Cancer
(IASLC)

Roy S Herbst MD PhD
Roy S. Herbst, MD, PhD
Professor of Medicine
Chief of Medical Oncology
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Smilow Cancer Hospital at Yale-New Haven
Yale School of Medicine
New Haven, CT

Corey J Langer MD
Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Vice Chair, Radiation Therapy Oncology Group
(RTOG)

Expert Faculty

Walter J Curran MD FACR
Walter J. Curran, Jr., MD
Executive Director
Winship Cancer Institute of Emory University
Professor & Chairman
Department of Radiation Oncology
Group Chairman
Radiation Therapy Oncology Group (RTOG)

Dr. Garon
Edward B. Garon, MD
Associate Professor of Medicine
Department of Medicine, Hematology/Oncology
Jonsson Comprehensive Cancer Center
Thoracic Oncology Program Area
University of California at Los Angeles School of Medicine
Los Angeles, CA

Barbara J Gitlitz MD
Barbara J. Gitlitz, MD
Associate Professor of Clinical Medicine
Department of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Fred R. Hirsch MD
Fred R. Hirsch, MD, PhD
Professor, Division of Medical Oncology
University of Denver School of Medicine
Denver, Colorado

John V Heymach MD PhD
John V. Heymach, MD, PhD
Professor of Thoracic Head/Neck Medical Oncology
Professor of Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Thomas J Lynch Jr MD
Thomas J. Lynch, Jr., MD
Professor of Medicine
Director, Yale Cancer Center
Physician-in-Chief,
Smilow Cancer Hospital, Yale-New Haven
New Haven, CT

Philip C Mack PhD
Philip C. Mack, PhD
Associate Adjunct Professor
Co-Leader Molecular Pharmacology
UC Davis Cancer Center
Sacramento, CA

Vincent A Miller MD
Vincent A. Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Suresh S Ramalingam MD
Suresh S. Ramalingam, MD
Director
Division of Medical Oncology
Associate Professor
Emory University School of Medicine
Atlanta, Georgia

Alan B Sandler MD
Alan B. Sandler, MD
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Oregon Health & Science University
Portland, OR

Joan H Schiller MD
Joan H. Schiller, MD
Professor & Division Chief
Hematology-Oncology
Deputy Director, Harold C. Simmons Cancer Center
Andrea L. Simons Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Dallas, TX
Chair, Lung Committee, Eastern Cooperative Oncology Group
(ECOG)

George R Simon MD FACP FCCP
George R. Simon, MD, FACP, FCCP
Associate Professor of Medicine & Oncology
The Burtschy Family Endowed Chair in Cancer Research
Assistant Director, Clinical Investigations, Hollings Cancer Center
Division of Hematology/Oncology, Department of Medicine
Medical University of South Carolina
Charleston, SC

Mark A Socinski MD
Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section, Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
Pittsburgh, PA

CASE-BASED LEARNING

Renaissance Los Angeles Airport Hotel
9620 Airport Boulevard, Los Angeles, CA 90045

Saturday, September 17, 2011

Personalized medicine for treating lung cancer is a reality. This past year there has been much new "practice-changing" data published that affects the optimal way to treat, manage and care for your patients with lung cancer. This symposium will help you improve your selection of the most appropriate new therapeutic strategies, and will also help you to identify the patient sub-populations of breast cancer who will respond to personalized therapies.

Taught by the top academic experts and best teachers, this is THE symposium on lung cancer that you should attend in 2011. This is the fourth year of this symposium and it continues to attract a full room of lung cancer clinicians who leave the program with the expert knowledge and competence needed to improve patient outcomes.
   
•
 Overview
•
 Educational Statement of Need
•
 Disclosure
•
 Target Audience
•
 Learning Objectives
•
 CME/CE Credit Information
•
 Agenda
•
 Renaissance Los Angeles Airport Hotel
•
 Registration
•
 Exhibit
•
 Southwest Airlines
   
Agenda
September 17, 2011 – Saturday
7:00AM Registration and Breakfast
7:50AM Welcome, Introductions and CME Pre-Activity Test Paul Bunn

Session 1: RETHINKING THE NSCLC THERAPY PARADIGM
CHAIR: Corey Langer
8:00AM The evolving algorithm for NSCLC: Moving beyond the traditional patient management to improve outcomes with new and emerging strategies. Paul Bunn
8:20AM How do we incorporate the new College of American Pathology /IASLC molecular biomarker testing guidelines into our routine NSCLC practices? Philip Mack
8:40AM Q & A Faculty & Learners

Session 2: PERSONALIZING EGFR-TARGETED THERAPY
CHAIR: Thomas Lynch

8:50AM Case Study: Personalizing therapy for NSCLC with EGFR inhibition strategies: The gold standard for outcomes. Thomas Lynch
9:10AM Case Study: Overcoming NSCLC resistance to EGFR inhibition: Incorporating novel strategies into therapy. Vincent Miller
9:30AM Case Study: How do we best utilize molecular biomarkers and testing beyond EGFR-mutation testing for optimal use of personalized EGFR-directed inhibition? Fred Hirsch
9:50AM Additional Interactive Case Studies Corey Langer
10:00AM Interactive Roundtable Panel Discussion and Q & A Faculty & Learners
10:15AM BREAK  

Session 3: PERSONALIZING LUNG CANCER TARGETS WITH CHEMOTHERAPY
CHAIR: Paul Bunn
10:30AM Enlisting the immune system and vaccines for NSCLC patients Paul Bunn
10:50AM Case Study: Switch maintenance therapy: What are the options for improving outcomes in NSCLC patients using chemotherapy, targeted therapy or both? Roy Herbst
11:10AM Additional Interactive Case Studies Edward Garon
11:25AM Case Study: Best practices and NSCLC outcomes with optimal clinical strategies using radiation plus chemotherapy: What is optimal? Walter Curran
11:45AM Interactive Roundtable Panel Discussion and Q & A Faculty & Learners
12:00PM LUNCH WITH THE PROFESSORS Faculty & Learners
1:00PM Case Study: What are best clinical practices for NSCLC relapses after initial and subsequent therapies? Barbara Gitlitz
1:20PM Case Study: Improving outcomes using novel and emerging strategies with chemotherapy: What are the new options for small cell lung cancer and NSCLC? Mark Socinski
1:40PM Case Study: How do we perform more effective biomarker testing for matching NSCLC patients with optimal therapy for maintenance of disease remission and after relapsed NSCLC? Philip Mack
2:00PM Session #3 Interactive Roundtable Panel Discussion and Q & A Faculty & Learners
Session 4: PERSONALIZING ANGIOGENESIS-TARGETED THERAPY
CHAIR: Joan Schiller
2:20PM Case Study: Rethinking patient eligibility for anti-angiogenic-based regimens in first-line therapy for advanced or metastatic non-squamous NSCLC: Are we maximizing our therapeutic options to help more patients? Alan Sandler
2:40PM Case Study: Examining the optimal clinical applications of anti-angiogenic-based NSCLC strategies to help more patients in the maintenance and second-line settings? John Heymach
3:00PM BREAK  
3:20PM Session #4 Interactive Roundtable Panel Discussion and Q & A Faculty & Learners
Session 5: EMERGING NSCLC TARGETS, NOVEL STRATEGIES AND OPPORTUNITIES FOR ENROLLMENT IN CLINICAL TRIALS
CHAIR: Roy Herbst
3:40PM Case Study: Histology and beyond: Personalizing first-line strategies employing chemotherapy for improving NSCLC outcomes George Simon
4:00PM Case Study: New developments for bone metastases: Do we have two viable options? Corey Langer
4:20PM NSCLC New pathways and targets: HER1, c-MET, EML4/ALK, PARP, Clusterin, HDAC, IGF-1R. How can inhibiting these improve outcomes? Suresh Ramalingam
4:40PM Final Interactive Roundtable Panel Discussion and Q & A Roy Herbst
4:55PM Concluding Remarks and CME Post Test via ARS Roy Herbst
5:00PM Adjourn All
Educational Grants

Sincere appreciation is extended to the following companies for their generous commercial support of this educational activity:



Shine a light on Lung Cancer
© 2012 Biomedical Learning Institute
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Biomedical Learning Institute(BLI) Web site reflects the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the BLI, the CME provider, or the commercial supporters providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified physician should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any BLI materials. Click here for our Privacy Policy.